When OFRM insiders can sell

…in exceptions, not to dispose of any shares of common stock, any options or warrants to purchase any shares of common stock or any securities convertible into or exchangeable for or that represent the right to receive shares of common stock during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus. When the lock-up period in these agreements expires, we and our stockholders will be able to sell shares in the public market. In addition, Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC may, together in their sole discretion, release all or some portion of the shares subject to the lock-up agreements prior to the expiration of the lock-up period. See "Certain Relationships and Related Party Transactions—Registration Rights Agreement." Sales of a substantial number of such shares, or the perception that…

Common stock to be outstanding after this offering 40,231,814 shares (or 41,881,395 shares if the underwriters exercise in full their option to purchase additional shares of common stock). Use of proceeds We estimate that we will receive net proceeds from this offering of approximately $111.7 million (or approximately $139.3 million if the underwriters exercise in full their option to purchase additional shares of common stock), based on an initial public offering price of $18.00 per share, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

…tock; (xii) with prior written consent of the representatives on behalf of the underwriters; or (xiii) to the underwriters pursuant to the underwriting agreement; (b) the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act; provided that no transfers occur under such plan during such lock-up period; and (c) pursuant to a bona fide third-party tender offer, merger, consolidation, or other similar transaction involving a change of control transaction and that has been made to all holders of our capital stock. Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC, in their sole discretion, may release the shares of common stock and other securities subject to the lock-up agreements described above in whole or in part at any time.

…directors, our executive officers, the selling stockholders, and substantially all of our other stockholders do not apply to, among other things, and subject in certain cases to various conditions: (a) transfers: (i) as bona fide gifts, charitable contributions, or for bona fide estate planning purposes; (ii) to any beneficiary of the holder pursuant to a will, other testamentary document, or intestate succession; (iii) to any member of the holder's immediate family or to any trust for the direct or indirect benefit of the holder or the immediate family of the holder; (iv) to a corporation, partnership, limited liability company, or…

…participant or will be a participant, in which: the amounts involved exceeded or will exceed $120,000; and any of our directors, executive officers, or holders of more than 5% of our capital stock, or any member of the immediate family of, or person sharing the household with, the foregoing persons, had or will have a direct or indirect material interest. Equity Financings Series D Preferred Stock Financing On February 28, 2022 and March 21, 2022, we sold an aggregate of 189,813 and 43,948 shares of our Series D Preferred Stock (the "Series D Preferred Stock Financing"), respectively, at a purchase price of $183.03 per share for an aggregate purchase price of $42.8 million.

…ed stock warrants issued with a debt facility into 103,896 shares of common stock at the then effective conversion ratio and exercise price, and does not include: (i) 5,477,425 shares of our common stock issuable on the exercise of stock options outstanding as of September 30, 2025 under our 2021 Omnibus Incentive Plan (the "2021 Plan"), (ii) 58,961 shares of our common stock reserved for future issuance under our 2021 Plan as of September 30, 2025, which shares cease to be available for issuance at the time the Company's omnibus equity incentive plan becomes effective upon the pricing of this offering (the "2026 Omnibus Plan"), (ii…